This test analyzes the quantity, proportion, and functional status of immune cells associated with autoimmune diseases to evaluate immune balance and chronic inflammation.

The test is recommended for individuals with autoimmune diseases, chronic inflammatory symptoms, immune dysfunction, treatment monitoring needs, or long-term health management goals.

The panel evaluates key immune cell populations including Treg cells, Th17 cells, CD4+ T cells, CD8+ T cells, B cells, NK cells, monocytes, and other immune-related biomarkers.

Yes. The test can track changes in immune cell profiles over time and help evaluate treatment response and disease progression.

Reports are typically available within 7–10 business days, with expedited processing available when necessary.

Fasting is generally not required. However, patients should inform their physician about current medications or immunosuppressive therapies before testing.